证券研究报告 | 医药生物 | 2025年4月12日 www.hczq.com 华创医药投资观点&研究专题周周谈·第121期 海外CXO 2024财报总结 本周周专题联系人：万梦蝶 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号: S0360523080008 邮箱: wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱 ...

Core Viewpoint - The company acknowledges potential impacts from the U.S. imposing tariffs on pharmaceuticals, particularly on its exports, which primarily consist of formulations [1] Group 1: Company Operations - The company's products exported to the U.S. are mainly formulations, with a significant portion produced domestically and some manufactured locally in the U.S. [1] - In 2023, revenue from the U.S. region accounted for approximately 13% of the company's total revenue [1] Group 2: Response Measures - The company may need to explore adjustments in production processes to mitigate the effects of potential tariffs, given the competitive pricing environment in the U.S. market [1] - The company is evaluating whether its U.S. production base can accommodate alternative production methods, with the possibility of relocating production facilities being considered [1] - The company has been actively pursuing global market expansion, although the U.S. market for formulations currently shows greater profitability [1]

Group 1: Kent Catalysts - Kent Catalysts is a major supplier in the field of phase transfer catalysts in China, with clients including Huahai Pharmaceutical, Wanhua Chemical, and Wanrun Co., and has entered the supply chains of well-known companies in the battery electrolyte sector [1][2] - The company focuses on the research, production, and sales of quaternary ammonium compounds, offering products such as quaternary ammonium salts, quaternary ammonium bases, and crown ethers, serving various industries including fine chemicals and battery electrolytes [2][3] - Kent Catalysts has achieved significant market share in the phase transfer catalyst sector through years of technological innovation and application, with revenue projections of 808 million yuan, 666 million yuan, and 617 million yuan for 2022-2024, and net profits of 110 million yuan, 85 million yuan, and 94 million yuan respectively [3] Group 2: Honggong Technology - Honggong Technology focuses on the automation processing lines and equipment for bulk materials, with a strong emphasis on providing tailored automation solutions based on customer needs across various industries including lithium batteries and fine chemicals [5][6] - The company has established good cooperative relationships with leading companies in the lithium battery industry, such as CATL and BYD, and has a significant market share [6] - Revenue projections for Honggong Technology are 2.178 billion yuan, 3.198 billion yuan, and 2.163 billion yuan for 2022-2024, with net profits of 298 million yuan, 315 million yuan, and 220 million yuan respectively [6]

Investment Rating - The report maintains an Equal-weight (EW) stance on MSCI China within the global EM/APXJ framework [9]. Core Insights - The report anticipates higher near-term market volatility due to the US imposing additional tariffs on China, raising the total tariff rate to up to 65% [2][4]. - The A-share market is viewed as better positioned for hedging and diversification compared to the offshore market, as A-share investors are less sensitive to tariff changes [3]. - The direct impact on earnings from the tariffs is expected to be smaller than the overall drag on macroeconomic growth, with the MSCI China universe generating only 13% of its total revenue from markets outside China, and less than 3% from the US [7]. Summary by Sections Market Volatility - The report highlights that the recent tariff hikes could lead to elevated market volatility as the market adjusts to the potential economic impacts [2][4]. A-Share Market Positioning - The A-share market is recommended for investors seeking stability, as it has shown lower correlation with global markets and less volatility compared to offshore markets [3]. Earnings Impact - The report suggests that the overall drag on equity market earnings will be less severe than the impact on macro growth, primarily due to the limited revenue exposure of listed Chinese companies to the US market [7]. Companies with High US Revenue Exposure - A list of 30 companies with the highest revenue exposure to the US market is provided, indicating potential negative impacts on these companies in the near term [8]. Key Indicators to Monitor - The report advises monitoring the USDCNY exchange rate, signs of US-China negotiations, and any significant policy easing measures to stabilize domestic growth [9].

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. announced that its major shareholder, Mr. Zhou Minghua, has pledged part of his shares, which may impact the company's stock performance and investor sentiment [1]. Group 1: Shareholder Information - Mr. Zhou Minghua holds a total of 224,418,890 shares, representing 14.88% of the company's total equity [1]. - After the recent pledge, Mr. Zhou has a total of 78,980,000 shares pledged, which accounts for 35.19% of his holdings and 5.24% of the company's total equity [1]. Group 2: Pledge Details - The pledged shares amount to 6,480,000 shares, with a pledge start date of April 1, 2025 [1]. - The company will continue to disclose information regarding the status of the pledged shares as necessary [3]. Group 3: Financial Health of Shareholder - Mr. Zhou Minghua is reported to have a good personal credit status and strong repayment ability, indicating that he is likely to manage any potential risks associated with the pledged shares [3].

Core Viewpoint - The article highlights the investment strategies of prominent fund managers as they reveal their hidden heavy holdings in various sectors, particularly focusing on innovative industries and technologies for 2025 [2][4][6][11]. Group 1: Fund Manager Strategies - Fund manager Ge Lan continues to focus on investment opportunities in the innovative pharmaceutical sector, with significant holdings in stocks like Pian Zai Huang and Renfu Pharmaceutical, which saw price increases of 37.10% and 26.01% respectively in the second half of 2024 [4][5]. - Zhou Weiwen has diversified his investments across multiple industries, including banking, insurance, and gaming, while expressing optimism about the artificial intelligence market in 2025 [2][6]. - Fu Pengbo maintains a high concentration of holdings, emphasizing increased attention to the technology sector and adjusting his portfolio to focus on emerging fields such as AI, AR/VR, and solid-state batteries [11][13]. Group 2: Performance of Hidden Heavy Holdings - Ge Lan's hidden heavy holdings in the healthcare sector, such as Xinyi Pharmaceutical, saw a remarkable increase of 2864.03% from mid-2024 to year-end [4]. - Zhou Weiwen's hidden heavy holdings, including China Pacific Insurance and Vanke, experienced notable price increases of 30.27% and 26.91% respectively in the latter half of 2024 [7]. - Fu Pengbo's hidden heavy holdings, like Quartz Co., saw a significant increase of 1236.93% in the second half of 2024, indicating strong performance in his concentrated portfolio [12]. Group 3: Market Outlook and Trends - The pharmaceutical industry is expected to continue facing volatility, with Ge Lan noting a lack of clear mainline logic for future growth despite supportive policies and improved market sentiment [4][5]. - Zhou Weiwen anticipates a recovery in industries currently at low points, such as chemicals and machinery, over the next two to three years, driven by favorable trends [8][9]. - Fu Pengbo believes that the technology sector will continue to evolve, presenting both challenges and opportunities for industry leaders and newcomers alike, with a focus on companies with solid fundamentals [13].

Investment Rating - The report maintains an "Accumulate" rating for the company [6] Core Views - The company has shown a recovery in performance and is actively expanding into new business areas [1] - The vitamin product segment is expected to recover, while the pharmaceutical segment remains under pressure [9] - The company is implementing a "vertical and horizontal" strategy to expand its business and new product offerings [9] Financial Performance Summary - The company's revenue for 2023 was 1,095 million, with a projected increase to 1,243 million in 2024, representing a year-on-year growth of 13.6% [5] - Operating profit is expected to rise from 207 million in 2023 to 355 million in 2024, reflecting a significant growth of 71.6% [5] - Net profit attributable to the parent company is forecasted to increase from 192 million in 2023 to 309 million in 2024, a growth of 60.8% [5] - Earnings per share are projected to grow from 0.35 in 2023 to 0.57 in 2024 [5] - The gross margin is expected to be 58.4% in 2024, with a net margin of 24.9% [5] Earnings Forecast and Investment Recommendations - The report adjusts revenue forecasts for vitamin products and pharmaceuticals while increasing the gross margin for vitamin products [3] - The projected earnings per share for 2025-2027 are 0.88, 1.05, and 1.36 respectively [3] - Based on comparable companies, a target price of 14.96 is set for 2025, corresponding to a 17 times price-to-earnings ratio [3]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance [5][7]. Core Views - The company is positioned as a leading player in the heparin raw material market, with a strong potential for growth in its API business due to improving market conditions [3][4]. - The company is focusing on its sterile injection formulations, which are experiencing rapid growth in overseas markets, supported by a robust product matrix and strategic acquisitions [4][61]. - The global biosimilar market is expected to expand significantly, and the company is well-positioned to capitalize on this trend through both self-developed products and strategic partnerships [5][67]. Summary by Sections 1. Company Overview - The company has transitioned from a traditional heparin raw material supplier to a high-end injection formulation and biosimilar provider, covering multiple therapeutic areas [13][16]. 2. Heparin API Market Improvement - The heparin raw material market is showing signs of recovery, with expectations for price stabilization and potential revenue growth for the company [3][31]. - The company has a strong production and sales level in its heparin API business, which is crucial for funding its injection formulation expansion [36][37]. 3. Focus on Sterile Injection Formulations - The company's injection business has seen significant revenue growth, with a 12.8% increase in 2023 and a compound annual growth rate (CAGR) of 47.4% from 2018 to 2023 [41][46]. - The company has a diverse product line in the injection segment, including low molecular weight heparin and anti-tumor agents, with a strong competitive position in the domestic market [47][55]. 4. Biosimilar Drug Development - The global biosimilar market is projected to grow rapidly, with the company actively developing multiple biosimilar products and securing market entry through strategic acquisitions [67][72]. - The company has made significant progress in obtaining FDA approvals for its biosimilar products, positioning itself as a key player in the U.S. market [72][73]. 5. Financial Projections - The company is expected to achieve substantial profit growth, with projected net profits of 9.0 billion, 11.9 billion, and 15.4 billion yuan for 2024, 2025, and 2026, respectively [5][6].

Financial Performance Forecast - The estimated net profit attributable to shareholders for 2024 is expected to be between 1,140 million and 1,240 million CNY, representing a year-on-year increase of approximately 30.953 million to 40.953 million CNY, or a growth rate of about 37.3% to 49.3%[3] - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is expected to be between 1,150 million and 1,250 million CNY, with a year-on-year increase of approximately 26.148 million to 36.148 million CNY, corresponding to a growth rate of about 29.4% to 40.7%[3] - The net profit for the same period last year was 830.466 million CNY, and the net profit after deducting non-recurring gains and losses was 888.522 million CNY[6] Factors Contributing to Profit Growth - The company attributes the significant profit growth to expanded sales scale, improved sales team structure, and effective market penetration strategies, along with the introduction of new products[7] - Continuous optimization of lean management and enhanced technical capabilities have contributed to improved cost control and increased gross margin, further strengthening the company's profitability[7] Performance Forecast Reliability - There are no major uncertainties affecting the accuracy of this performance forecast[8] - The performance forecast data is preliminary and has not been audited by an accounting firm; the final figures will be disclosed in the official 2024 annual report[9]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2024-134 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于"华海转债"可选择回售的第九次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2024 年 11 月 2 日 至 2024 年 12 月 13 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下简 称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开发 行可转换公司债券募集说明书》（以下简称《募集说明书》）的约定，可转债回售条 款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证券 交易所股票上市规则》和《浙江华海药业股份有限公司公开发行可转换公司债券募 集说明书》等有关规定，就回售有关事项向全体"华海转债"持有人公告如下： ...